Heat Biologics Presents New Preclinical Data from OncoSec Collaboration at the American Association for Cancer Research (AACR) Annual Meeting Apr 5, 2017
Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor Mar 21, 2017
Heat Biologics, Inc. to Present at The MicroCap Conference on April 4th in New York City Mar 20, 2017
Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2 Mar 13, 2017